The Medscape Division of Public Health announced the launch of the "Where Public Health Meets Practice" Learning Center, a dedicated educational destination ...

UK biotech N4 Pharma, a company developing a gene delivery system to enable advanced therapies for cancer and other diseases, ...

The US Food and Drug Administration (FDA) has issued draft guidance for sponsors seeking approval for targeted individualised ...

Rare disease launches are complex by nature. Yet one of the most consistent risks we see is rarely treated as a launch issue at all: stigma.

Stop pushing content at a burnt-out audience and start creating "Digital Magnetism." Join Impetus Digital to unlock the 2026 ...

The study finds that healthcare settings are a leading source of stigma for people living with rare conditions ...

Many of the people most engaged with our poster were already advocates, which may explain why the focus shifted quickly to ...

In a deal worth $950m, GSK has agreed to acquire 35Pharma, a private, clinical-stage biopharmaceutical company based in Canada that specialises in the development of novel protein-based therapeutics.

Precision intelligence offers a path forward – pharma-specific, human-led and already in use by teams managing complex, ...

As of 1 January 2027, Novo Nordisk will lower the list price, or wholesale acquisition cost, to $675 for Wegovy (semaglutide) ...

Ethan Mollick’s idea of the ‘jagged frontier’ of AI 1 is one of the most useful ways of describing the problem with the ...

These rules apply to pharma. For distribution, medicine approvals and access are essential. For mental availability, brands ...